Cargando…

The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer

Reprogramming of energy metabolism is one of the basic characteristics of cancer and has been proved to be an important cancer treatment strategy. Isocitrate dehydrogenases (IDHs) are a class of key proteins in energy metabolism, including IDH1, IDH2, and IDH3, which are involved in the oxidative de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yang, Xu, Wei, Li, Mingxue, Yang, Yueying, Sun, Dejuan, Chen, Lidian, Li, Hua, Chen, Lixia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149907/ https://www.ncbi.nlm.nih.gov/pubmed/37139412 http://dx.doi.org/10.1016/j.apsb.2022.12.019

Ejemplares similares

Studies on the regulatory mechanism of isocitrate dehydrogenase 2 using acetylation mimics
por: Xu, Yuqun, et al.
Publicado: (2017)

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
por: Golub, Danielle, et al.
Publicado: (2019)

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
por: Liu, Xiaoyan, et al.
Publicado: (2019)

Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism
por: Su, Li, et al.
Publicado: (2020)

Molecular mechanism of the dual regulatory roles of ATP on the αγ heterodimer of human NAD-dependent isocitrate dehydrogenase
por: Sun, Pengkai, et al.
Publicado: (2020)

Isocitrate dehydrogenase mutations in myeloid malignancies
por: Medeiros, B C, et al.
Publicado: (2017)

Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma
por: Yan, Dongming, et al.
Publicado: (2022)

Effects of cancer-associated point mutations on the structure, function, and stability of isocitrate dehydrogenase 2
por: Chen, Xiang, et al.
Publicado: (2022)

Identification of a New Selective Chemical Inhibitor of Mutant Isocitrate Dehydrogenase-1
por: Kim, Hyo-Joon, et al.
Publicado: (2015)

Differentiating Inhibition Selectivity and Binding Affinity of Isocitrate Dehydrogenase 1 Variant Inhibitors
por: Liu, Shuang, et al.
Publicado: (2023)

Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight
por: Al-Khallaf, Hamoud
Publicado: (2017)

Isocitrate dehydrogenase gene variants in cancer and their clinical significance
por: Cadoux-Hudson, Thomas, et al.
Publicado: (2021)

Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations
por: Hvinden, Ingvild Comfort, et al.
Publicado: (2021)

Radiomic model for predicting mutations in the isocitrate dehydrogenase gene in glioblastomas
por: Hsieh, Kevin Li-Chun, et al.
Publicado: (2017)

Characterization of the Isocitrate Dehydrogenase Gene Family and Their Response to Drought Stress in Maize
por: Wei, Ningning, et al.
Publicado: (2023)

Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1
por: Fujiwara, Hiroaki, et al.
Publicado: (2018)

The Role of Isocitrate Dehydrogenases in Direct Reprogramming to Cardiomyocytes
por: Ishida, Tomoaki, et al.
Publicado: (2021)

Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
por: Liu, Yang, et al.
Publicado: (2020)

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
por: Mellinghoff, Ingo K., et al.
Publicado: (2020)

Arf6 as a therapeutic target: Structure, mechanism, and inhibitors
por: Sun, Dejuan, et al.
Publicado: (2023)

Identification of medicinal compounds as potential inhibitors for mutated isocitrate dehydrogenases against chondrosarcoma
por: Shah, Fahad Hassan, et al.
Publicado: (2022)

Insights into the inhibitory mechanisms of NADH on the αγ heterodimer of human NAD-dependent isocitrate dehydrogenase
por: Liu, Yabing, et al.
Publicado: (2018)

The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells
por: Smolková, Katarína, et al.
Publicado: (2012)

Isocitrate dehydrogenase variants in cancer — Cellular consequences and therapeutic opportunities
por: Liu, Shuang, et al.
Publicado: (2020)

Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas
por: Chen, Jun-Rui, et al.
Publicado: (2016)

Arteriovenous malformation within an isocitrate dehydrogenase 1 mutated anaplastic oligodendroglioma
por: Lai, Grace, et al.
Publicado: (2015)

Silybin suppresses ovarian cancer cell proliferation by inhibiting isocitrate dehydrogenase 1 activity
por: Wei, Zibo, et al.
Publicado: (2022)

Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas
por: Li, Ming-Yang, et al.
Publicado: (2015)

Prognostic and diagnostic potential of isocitrate dehydrogenase 1 in esophageal squamous cell carcinoma
por: Chen, Xuan, et al.
Publicado: (2016)

Molecular mechanism of the allosteric regulation of the αγ heterodimer of human NAD-dependent isocitrate dehydrogenase
por: Ma, Tengfei, et al.
Publicado: (2017)

Structure and allosteric regulation of human NAD-dependent isocitrate dehydrogenase
por: Sun, Pengkai, et al.
Publicado: (2020)

Potential Mitochondrial Isocitrate Dehydrogenase R140Q Mutant Inhibitor from Traditional Chinese Medicine against Cancers
por: Lee, Wen-Yuan, et al.
Publicado: (2014)

Mechanisms underlying the biological changes induced by isocitrate dehydrogenase-1 mutation in glioma cells
por: WANG, JU-BO, et al.
Publicado: (2014)

Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays
por: Urban, Daniel J., et al.
Publicado: (2017)

Isocitrate protects DJ-1 null dopaminergic cells from oxidative stress through NADP(+)-dependent isocitrate dehydrogenase (IDH)
por: Yang, Jinsung, et al.
Publicado: (2017)

Isocitrate dehydrogenase mutations: new opportunities for translational research
por: Keum, Young-Sam, et al.
Publicado: (2015)

Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma
por: Alzial, Gabriel, et al.
Publicado: (2021)

Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis
por: OHBA, Shigeo, et al.
Publicado: (2016)

Isocitrate Dehydrogenase 1 and 2 Mutations in Pediatric Neuroblastoma Patients
por: LEVENTOGLU, Emre, et al.
Publicado: (2023)

Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat
por: Chang, Chi-Ming, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4bttrejqbkf2rp0jd30pmbje17